In this week’s video, Dr. Brian G.M. Durie discusses current treatments, including immune therapies, used to target and eliminate myeloma cells.

BOTTOM LINE:
Genetic mutations create “parameters” that anti-myeloma therapies can target.

Have a question? Submit it to [email protected]

IMF Chairman Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected]

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Is there a link between MGUS and kidney damage in myeloma patients?
Next Post
Cures Reported for Two Blood Diseases in One Week: Can Either One Be Applied to Myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.